Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
Bipartisan Bill to Ban Noncompete Clauses Introduced in OH Ohio Sens. Bill Blessing (R) and Bill DeMora (D) have introduced legislation ( SB 11 ) that would ban employers from enforcing noncompete clauses...
IN Senate Passes Under-16 Social Media Ban Indiana’s Senate passed a bill ( SB 11 ) that would prohibit social media companies from allowing those under the age of 16 from accessing their platforms...
Lawsuit Accuses GoodRX, PBMs of Price-Fixing A proposed class action lawsuit filed in federal court in California alleges online prescription drug price comparison platform GoodRx and several pharmacy...
The wildfires in Los Angeles this month have done more than just upended lives and destroyed millions of dollars’ worth of property . They’ve also wreaked havoc with an insurance market that...
NY to Weigh AI Companion Chatbot Liability New York Assemblyman Clyde Vanel (D) is drafting a bill that would make developers of AI companion chatbots liable for harm those chatbots cause to minors....
With popular weight-loss drugs like Mounjaro, Ozempic and Wegovy in short supply, many doctors, pharmacies and other providers have begun offering compounded versions of the drugs tailored to the needs of individual patients. They’re allowed to do so because the active ingredients in the drugs—semaglutide or tirzepatide—are listed on the U.S. Food and Drug Administration’s drug shortage list.
While commercial drugs are regulated by the FDA, states are responsible for the licensing and oversight of compounding pharmacies, and they’re now struggling to stay on top of that job. Idaho and Tennessee recently announced investigations of medical spas and other providers that may have been dispensing compounded weight-loss drugs illegally. And California and other states are considering strengthening their oversight of providers that offer such drugs. (NATIONAL CONFERENCE OF STATE LEGISLATURES)
Vermont Attorney General Charity Clark (D) filed a lawsuit against pharmacy benefit managers Express Scripts and CVS Caremark, accusing them of squeezing out competition and driving up prescription drug costs. The suit claims the two PBMs control more than 95% of Vermont’s pharmacy benefit market, giving them the power to dictate which drugs are covered by insurers. (LAW360)
AstraZeneca and AbbVie have filed lawsuits challenging legislation enacted in Kansas in April (SB 28) preventing drug companies from limiting the ability of pharmacies under contract with eligible hospitals and clinics to obtain outpatient prescription drugs at discounted prices, as provided for by the federal 340B drug discount program. The drug makers claim the federal program wasn’t intended to cover pharmacy chains like CVS and Walgreens. (KANSAS REFLECTOR)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.